Skip to main content
SpringerLink
Log in

The Use of Chemotherapy in the Management of Patients with Malignant Melanoma

  • Chapter
Cutaneous Melanoma and Precursor Lesions

Part of the book series: Developments in Oncology ((DION,volume 25))

  • 37 Accesses

Abstract

Chemotherapy of melanoma is often of limited benefit to the patient with disseminated disease. In many trials of either single agents or combinations, response rates are between 20 and 30%. Most of the responding patients in these trials have partial remissions and often the difference between the mean survivals of responding and non-responding patients is 4 months at most. Even this difference may not indicate that there is a real benefit in terms of life prolongation for the patient responding to chemotherapy. Patients with a limited tumour burden and only few metastases have a longer life expectation than patients with many metastases at multiple sites. Since more patients with limited dissemination respond to chemotherapy than those with the more extensive disease it is not a surprise to find a longer survival in responding patients. For instance in a study of high-dose melphalan and autologous bone marrow transplantation, in-which a response rate of 12/28 (43%) was found, a median survival of 9 months for responders and 4 for non-responders was measured. But when analyzed from the time of first recorded evidence of distant metastases, no real difference in survival between responders and non- responders was observed (1).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Cornbleet MA, McElwain TJ, Kumar PJ, et al. Treatment of advanced malignant melanoma with high-dose melphalan and autologous bone marrow transplantation. Br J Cancer 1983; 48: 329–34.

    Article  PubMed  CAS  Google Scholar 

  2. Beretta G, Bonadonna G, Cascinelli N, et al. Comparative evaluation of three combination regimens for advanced malignant melanoma: Results of an international cooperative study. Cancer Treat Rep 1976; 60: 33–40.

    PubMed  CAS  Google Scholar 

  3. Stevens MFG. A springboard to new antitumour agents. In: Structure-Activity Relationships of Anti-Tumour Agents. (Eds) Reinhoudt DN, Connors TA, Pinedo HM, Van de Poll, Kft. The Hague: Martinus Nijhoff Publishers, pp. 183–218, 1983.

    Google Scholar 

  4. Bellet RE, Mastrangelo MJ, Berd D, et al. Chemotherapy of metastatic malignant melanoma. In: Human Malignant Melanoma. (Eds) Clark WH, Goldman LI, Mastrangelo MJ, New York: Grune and;Stratton, pp. 325–51, 1979.

    Google Scholar 

  5. Costanza ME, Nathanson L, Schoenfeld D, et al. Results with methyl-CCNU and DTIC in metastatic melanoma. Cancer 1977; 40: 1010–5.

    Article  PubMed  CAS  Google Scholar 

  6. Hill GJ, Krementz ET. Duration of remission following complete response (CR) to chemotherapy for metastatic melanoma. Proc Amer Assoc Cancer Res 1980; 21: 188.

    Google Scholar 

  7. Nathanson L, Wolter J, Horton J, et al. Characteristics of prognosis and response to imidazole carboxamide in malignant melanoma. Clin Pharmaol Ther 1971; 12: 955–62.

    CAS  Google Scholar 

  8. Pritchard KI, Quirt IC, Cowan DH, et al. DTIC therapy in metastatic malignant melanoma: a simplified dose schedule. Cancer Treat Rep 1980; 64: 1123–6.

    PubMed  CAS  Google Scholar 

  9. Jortay AM, Lejeune FJ, Kenis Y. Regional chemotherapy of maxillo-facial malignant melanoma with intracarotid artery infusion of DTIC. Tumori 1977; 63: 299–302.

    PubMed  CAS  Google Scholar 

  10. Lejeune FJ, Jortay AM, Dor P. Intracarotid artery infusion of DTIC for invasive maxillofacial melanoma. In: Vascular Perfusion in Cancer Therapy. Rec Res Cancer Res, vol. 86. (Eds) Schwemmle K, Aigner K. Berlin: Springer-Verlag, pp. 162–4, 1983.

    Google Scholar 

  11. Storm FK, Kaiser LR, Goodnight JE, et al. Thermochemo- therapy for melanoma metastases in liver. Cancer 1982; 49: 1243–8.

    Article  PubMed  CAS  Google Scholar 

  12. Retsas S, Pickering D, Plant G, et al. DTIC as a second line treatment in advanced malignant melanoma. Proc Amer Soc Clin Oncol 1980; 21: 369.

    Google Scholar 

  13. Koriech, OM, Shukla VS. Dacarbazine (DTIC) in malignant melanoma: reduced toxicity with protection from light. Clin Radiol 1981; 32: 53–5.

    Article  PubMed  CAS  Google Scholar 

  14. Sava G, Giraldi T, Lassiani L, et al. Antimetastatic action and hematological toxicity of p-(3,3-dimethyl-l- triazeno) benzoic acid potassium salt and 5-(3,3- dimethyl-l-triazeno)imidazole-4-carboxamide used as prophylactic adjuvants to surgical tumor removal in mice bearing B16 melanoma. Cancer Res 1984; 44: 64–8.

    PubMed  CAS  Google Scholar 

  15. Retsas S, Newton KA, Westbury G. Vindesine as a single agent in the treatment of advanced melanoma. J Cancer Chemother Pharmacol 1979; 2: 257–60.

    CAS  Google Scholar 

  16. Smith IC, Hedley DW, Powles TJ, et al. Vindesine: a phase II study in the treatment of breast carcinoma, malignant melanoma and other tumors. Cancer Treat Rep 1978; 62: 1427–33.

    PubMed  CAS  Google Scholar 

  17. Rümke P. Malignant melanoma. In: Cancer. Chemotherapy 1983. The EORTC Cancer Chemotherapy Annual 5. (Eds) Pinedo HM, Chabner B. Amsterdam: Elsevier, pp. 423–9, 1983

    Google Scholar 

  18. Rümke P. Malignant melanoma. In: Cancer Chemotherapy 1984. The EORTC Cancer Chemotherapy Annual 6. (Eds) Pinedo HM, Chabner B. Amsterdam: Elsevier, 1984: in press.

    Google Scholar 

  19. Carmichael J, Atkinson RJ, Caiman KC, et al. A multicentre phase II trial of vindesine in malignant melanoma. Eur J Cancer Clin Oncol 1982: 18: 1293–5.

    Article  PubMed  CAS  Google Scholar 

  20. Costanzi JJ. The chemotherapy of human malignant melanoma. In: Malignant Melanoma 1. Cancer Treatment and Research, Vol. 9. (Ed) Costanzi JJ. The Hague: Martinus Nijhoff Publishers, pp. 259–74, 1983.

    Google Scholar 

  21. Spitzer G, Dicke KA, Verma DS, et al. High dose BCNU therapy with autologous bone marrow infusion: preliminary observations. Cancer Treat Rep 1979; 63: 1257–64.

    PubMed  CAS  Google Scholar 

  22. Fay JW, Levine MN, Phillips GL, et al. Treatment of metastatic melanoma with intensive 1,3-bis(2-chloro- ethyl)-1-nitrosourea (BCNU) and autologous bone marrow transplantation (AMTX). Proc Amer Soc Clin Oncol 1981: 22: 532.

    Google Scholar 

  23. Madajewicz S, West CR, Park HC, et al. Phase II study - intra-arterial BCNU-therapy for metastatic brain tumors. Cancer 1981; 47: 653.

    Article  PubMed  CAS  Google Scholar 

  24. Dufour FD, Eilber FR, Morton DL. High-dose methotrexate combined with DTIC for metastatic melanoma. Proc Amer Assoc Cancer Res 1978; 19: 360.

    Google Scholar 

  25. Karakousis CP, Carlson M. High-dose methotrexate in malignant melanoma. Cancer Treat Rep 1979; 63: 1405–7.

    PubMed  CAS  Google Scholar 

  26. Fisher RI, Chabner BA, Myers CE. Phase II study of high-dose methotrexate in patients with advanced malignant melanoma. Cancer Treat Rep 1979; 63: 147–8.

    PubMed  CAS  Google Scholar 

  27. Frei E, Blum RH, Pitman SW, et al. High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity. Amer J Med 1980; 68: 370–6.

    Article  PubMed  Google Scholar 

  28. Leahy MF, Silver HKB, Klimo P, et al. Treatment of advanced malignant melanoma with high dose methotrexate and folinic acid rescue. Med Paed Oncol 1982; 10: 151–6.

    Article  CAS  Google Scholar 

  29. Comis Rl, Carter SK. Integration of chemotherapy into combined modality therapy of solid tumors: IV Malignant melanoma. Cancer Treat Rev 1974; 1: 285–304.

    Article  PubMed  CAS  Google Scholar 

  30. Luce JK. Chemotherapy of malignant melanoma. Cancer 1972; 30: 1604–17.

    Article  PubMed  CAS  Google Scholar 

  31. Bulman AS, Jamieson CW. Isolated limb perfusion with melphalan in the treatment of malignant melanoma. Br J Surg 1980; 67: 660–2.

    Article  PubMed  CAS  Google Scholar 

  32. Minor D, Allen R, Alberts D, et al. Pharmacokinetics of isolated limb perfusion with heat and melphalan for melanoma. Proc Amer Soc Clin Oncol 1983; 2: 239.

    Google Scholar 

  33. Lejeune FJ, Deloof T, Ewalenko P, et al. Objective regression of unexcised melanoma in in-transit metastases after hyperthermic isolation perfusion of the limbs with melphalan. In: Vascular Perfusion in Cancer Therapy. Rec Res Cancer Res, vol. 86. (Eds) Schwemmle K, Aigner K, Berlin: Springer-Verlag, pp. 268–76, 1983.

    Google Scholar 

  34. Al-Sarraf M, Fletcher W, Oishi N, et al. Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: a Southwest Oncology Group study. Cancer Treat Rep 1982; 66: 31–6.

    PubMed  CAS  Google Scholar 

  35. Voigt H, Meigel WN, Meissner K, et al. Erfahrungen mit der hochdosierten Cis-Platin-Therapie beim metasta- sierten malignen Melanom. Onkologie 1982; 5: 120–9.

    Article  PubMed  CAS  Google Scholar 

  36. Mechl Z, Krejci P. Cis-diaminedichloroplatinum in the treatment of disseminated malignant melanoma. Neoplasma 1983; 30: 371–7.

    PubMed  CAS  Google Scholar 

  37. Rümke P. Malignant melanoma. In: Cancer Chemotherapy 1979. The EORTC Cancer Chemotherapy Annual 1. (Ed) Pinedo HM. Amsterdam: Excerpta Medica, pp. 412–23, 1979.

    Google Scholar 

  38. Rümke P. Malignant melanoma. In: Cancer Chemotherapy 1980. The EORTC Cancer Chemotherapy Annual 2. (Ed) Pinedo HM, Amsterdam: Excerpta Medica, pp. 380–92, 1980.

    Google Scholar 

  39. Rümke P. Malignant melanoma. In: Cancer Chemotherapy 1981. The EORTC Cancer Chemotherapy Annual 3. (Ed) Pinedo HM, Amsterdam: Excerpta Medica, pp. 397–408, 1981.

    Google Scholar 

  40. Rümke P. Malignant melanoma. In: Cancer Chemotherapy 1982. The EORTC Cancer Chemotherapy Annual 4. (Ed) Pinedo HM, Amsterdam: Excerpta Medica, pp. 364–72, 1982.

    Google Scholar 

  41. Fisher RI, Young RC, Lippman ME. Diethylstilbestrol therapy in surgically non-resectable melanoma. Proc Amer Assoc Cancer Res 1978; 19: 339.

    Google Scholar 

  42. Neifeld J, Lippman M. Steroid hormone receptors and melanoma. J Invest Dermatol 1980; 74: 379–81.

    Article  PubMed  CAS  Google Scholar 

  43. Lopez R, Karakousis CP, Didolkar MS, et al. Estramustine phosphate in the treatment of advanced malignant melanoma. Cancer Treat Rep 1978; 62: 1329–32.

    PubMed  CAS  Google Scholar 

  44. Beretta G, Tabiadon D, Fossati P. Clinical evaluation of medroxiprogesterone acetate (MAP) in malignant melanoma. Cancer Treat Rep 1979; 63: 1200.

    Google Scholar 

  45. Creagan ET, Schutt AJ, Ahmann DL, et al. Phase II study of high-dose megestrolacetate in patients with advanced malignant melanoma. Cancer Treat Rep 1982; 66: 1239–40.

    PubMed  CAS  Google Scholar 

  46. Fisher RI, Neifeld JP, Lippman ME. Oestrogen receptors in human malignant melanoma. Lancet 1976; ii: 337–8.

    Google Scholar 

  47. Nazzaro-Porro M, Zina G, Breathnach A, Effect of azelaic acid on human malignant melanoma. Lancet 1980; i: 1109-11.

    Google Scholar 

  48. Editorial. Vitamin A and cancer. Lancet 1980; i: 575–6.

    Google Scholar 

  49. Schroder EW, Black PH. Retinoids: tumor preventers or tumor enhancers. J Natl Cancer Inst 1980; 65: 671–4.

    PubMed  CAS  Google Scholar 

  50. Meyskens Jr FL, Salmon SE. Inhibition of human melanoma colony formation by retinoids Cancer Res 1979; 39: 4055–7.

    Google Scholar 

  51. Levine N, Meyskens FL. Topical vitamin-A-acid therapy for cutaneous metastatic melanoma. Lancet 1980; ii: 224–6.

    Google Scholar 

  52. Morgan BDG, O°Neill T, Dewey DL, et al. Treatment of malignant melanoma by intravascular 4-hydroxyanisol. Clin Oncol 1981; 7: 227–34.

    PubMed  CAS  Google Scholar 

  53. Neifeld JP, Tormey DC, Baker A, et al. Phase II trial of a dopaminergic inhibitor in previously treated melanoma patients. Cancer Treat Rep 1983; 67: 155–8.

    PubMed  CAS  Google Scholar 

  54. Taub RN, Baker MA. Treatment of metastatic malignant melanoma with pimozide. Lancet 1979; i: 605.

    Google Scholar 

  55. Hill GF, Metter GE, Krementz ET, et al. DTIC and combination therapy for melanoma. II. Escalating schedules of DTIC with BCNU, CCNU and vincristine. Cancer Treat Rep 1979; 63: 11–2.

    Google Scholar 

  56. Costanza ME, Nathanson L, Lenhard R, et al. Therapy of malignant melanoma with an imidazole carboxamide and biscchlorethyl nitrosourea. Cancer 1972; 30: 1456–61.

    Article  Google Scholar 

  57. Carter RD, Krementz ET. DTIC in combination therapy for metastatic melanoma. A COG cooperative study. Proc Amer Assoc Cancer Res 1975; 16: 16.

    Google Scholar 

  58. Costanzi JJ, Al-Sarraf M, Groppe C, et al. Combination chemotherapy plus BCG in the treatment of disseminated malignant melanoma: a Southwest Oncology Group study. Med Paed Oncol 1982; 10: 251–8.

    Article  CAS  Google Scholar 

  59. Costanzi JJ, Fletcher WS, Balcerzak SP, et al. Combi¬nation chemotherapy plus levamisole in the treatment of disseminated malignant melanoma. A Southwest Oncology Group study. Cancer 1984; 53: 833–6.

    Article  PubMed  CAS  Google Scholar 

  60. Chiba M, Jimbow K, Kizukuri K, et al. Chemoimmunotherapy for disseminated malignant melanoma with DTIC, ACNU, VCR and OK432. J Dermatol 1982; 9: 23–30.

    PubMed  CAS  Google Scholar 

  61. Robidoux A, Gutterman JU, Body GP, et al. Actinomycin-D plus 5-(3,3-dimethyl-l-triazeno)-imidazole-4-carboxamide (DTIC) with or without intravenous Corynebacterium parvum in metastatic malignant melanoma. Cancer 1982; 49: 2246–51.

    Article  PubMed  CAS  Google Scholar 

  62. Presant CA, Bartolucci AA, Balch C, A randomized comparison of cyclophosphamide, DTIC with or without piperazinedione in metastatic malignant melanoma. Cancer 49; 1355–7.

    Google Scholar 

  63. Samson NK, Baker LH, Cummings G, et al. Clinical trial of chlorozotocin, DTIC, and dactinomycin in metastatic malignant melanoma. Cancer Treat Rep 1982; 66: 371–4.

    PubMed  CAS  Google Scholar 

  64. Costanzi JJ, Al-Sarraf M, Frank J. Chemoimmunotherapy in disseminated melanoma: a Southwest Oncology Group study. Proc Amer Soc Clin Oncol 1982; 1: 169.

    Google Scholar 

  65. Retsas S, Athanasiou A, Flynn MD, et al. Combination chemotherapy with vindesine and DTIC in advanced malignant melanoma. Proc Amer Soc Clin Oncol 1982; 1: 169.

    Google Scholar 

  66. Samson MK, Baker LH, Haas CD. Dibromodulcitol (DBD), DTIC (D) and actinomycin D (A) in metastatic malignant melanoma. Proc Amer Soc Clin Oncol 1: 172.

    Google Scholar 

  67. Yap, B-S, Burgess MA, Benjamin RS, et al. DTIC and continuous 5-day infusion of vindesine + IV MER for metastatic malignant melanoma. Proc Amer Soc Clin Oncol 1982; 1: 178.

    Google Scholar 

  68. Seigler HF, Lucas Jr VS, Pickett NH, et al. DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma. Cancer 1980; 46: 2346–8.

    Article  PubMed  CAS  Google Scholar 

  69. Ahn SS, Giuliano A, Kaiser L, et al. The limited role of BOLD chemotherapy for disseminated malignant melanoma. Proc Amer Soc Clin Oncol 1983; 2: 228.

    Google Scholar 

  70. Jose DG, Minty CC, Hillcoat B. BOLD chemotherapy in patients with disseminated malignant melanoma. Med Paed Oncol 1983; 11: 199.

    Google Scholar 

  71. Cohen SM, Ohnuma T, Cheung T, et al. Bleomycin, carmus- tine, vincristine, and dacarbazine in patients with metastatic malignant melanoma. Cancer Treat Rep 1983; 67: 947–8.

    PubMed  CAS  Google Scholar 

  72. Byrne MJ, Reynolds PM. Phase II study of cyclophospha¬mide, vincristine and DTIC + BCG in the treatment of malignant melanoma. Austr NZ J Med 1982; 12: 263–6.

    Article  CAS  Google Scholar 

  73. Mulder JH, Dodion P, Cavalli F, et al. Cisplatin and vindesine combination chemotherapy in advanced malignant melanoma: an EORTC phase II study. Eur J Cancer Clin Oncol 1982; 18: 1297–302.

    Article  PubMed  CAS  Google Scholar 

  74. Luikart SD, Kirkwood JM. A comparison of vinblastine/ bleomycin/cis-platin (VBD) with dacarbazine (DTIC) in metastatic melanoma. Proc Amer Soc Clin Oncol 1982; 1: 176.

    Google Scholar 

  75. Bajetta E, Rovej R, Buzzoni R, et al. Treatment of advanced malignant melanoma with vinblastine, bleomycin, and cisplatin. Cancer Treat Rep 1982; 66: 1299–302.

    PubMed  CAS  Google Scholar 

  76. Creagan ET, Ahmann DL, Schutt AJ, et al. Phase II study of combination of vinblastine, bleomycin, and cisplatin in advanced malignant melanoma. Cancer Treat Rep 1982; 66: 567–70.

    PubMed  CAS  Google Scholar 

  77. York RM, Lawson DH, McKay J. Treatment of metastatic malignant melanoma with vinblastine, bleomycin by infusion and cisplatin. Cancer 1983; 52: 2220–2.

    Article  PubMed  CAS  Google Scholar 

  78. Mechl Z, Nekulova M, Sopkova B,The VDB regimen (vinblastin - bleomycin - cisplatinum) with high dosis of cisplatinum in the therapy of advanced malignant melanoma. Proc 13th Int Congress of Chemotherapy, Vienna, Part 246: Melanoma, (Eds) Cascinelli N, Kokoschka EM, p. 246 /22, 1983.

    Google Scholar 

  79. Carey RW, Green MR, Anderson J. Vinblastine-dimethyl- triazenoimidazole carboxamide (DTIC)-Cis-platinum (VDP): Active regimen in metastatic melanoma. Proc Amer Soc Clin Oncol 1983; 2: 237.

    Google Scholar 

  80. Carmo-Pereira J, Costa FO, Henriques E. Triple combination cytotoxic chemotherapy with CCNU, procarbazine and vincristine in disseminated malignant melanoma: 7- years’ follow-up. Proc Amer Soc Clin Oncol 1983: 2: 227.

    Google Scholar 

  81. Creagan ET, Ahmann DL, Schutt AJ. Phase II study of mitolactol and semustine combination chemotherapy for advanced malignant melanoma. Cancer Treat Rep 1982; 66: 1425–6.

    PubMed  CAS  Google Scholar 

  82. Chauvergne J, Bui NB, Cappelaere P, et al. Chimio- therapie des melanomes malins evolues. Risultats d1un essai controle comparant ’association de detorubicine et de dacarbazine (DTIC) a la dacarbazine seule. Sem Hop Paris 1982; 58: 2697.

    Google Scholar 

  83. Becerano S, Knobler R, Kokoschka EM. Randomized chemo-therapy study in malignant melanoma stage III. BiCNU + cis platin versus vindesine + BiCNU + cis platin. Preliminary report. Proc 13th Int Congress of Chemotherapy, Vienna, Part 246: Melanoma, (Eds) Cascinelli N, Kokoschka EM, p. 246 /31, 1983.

    Google Scholar 

  84. Costanzi J, Fabian C, Wilson H, et al. Sequential combination chemotherapy for disseminated melanoma: A Southwest Oncology Group study. Cancer Treat Rep 1981; 65: 732–4.

    PubMed  CAS  Google Scholar 

  85. Baldwin RW. Immunotherapy of tumors. In: Cancer Chemo-therapy 1981. The EORTC Cancer Chemotherapy Annual 3 (Ed) Pinedo HM, Amsterdam: Excerpta Medica, pp. 178 - 202, 1981.

    Google Scholar 

  86. Stephens CL. Complement-induced entry of membrane- impermeable material into tumour cells: possibilities for chemotherapy. Clin Immunol Immunopathol 1981; 18: 254–60.

    Article  PubMed  CAS  Google Scholar 

  87. Hollinshead A, Arlen M, Yonemoto R, et al. Pilot studies using melanoma-associated antigens (TAA) in specific- active immunochemotherapy of malignant melanoma. Cancer 1982; 49: 1387–404.

    Article  PubMed  CAS  Google Scholar 

  88. Rümke P, Israels SP. Topical DNCB followed by systemic DTIC treatment in melanoma patients with skin metastases ± other metastases. Proc 2nd European Conference on Clinical Oncology, November 1983, Amsterdam, p. 131, abstract 11-06.

    Google Scholar 

  89. Flodgren P, Borgstrom S, Jonsson PE, et al. Metastatic malignant melanoma: Regression induced by combined treatment with interferon (HuIFN- (Le)) and cimetidine. Int J Cancer 1983; 32: 657–65.

    Article  PubMed  CAS  Google Scholar 

  90. Hill NO, Pardue A, Khan A, et al. Treatment of malignant melanoma with a combination of interferon alpha and cimetidine. Proc Amer Assoc Clin Oncol 1983; 2: 47.

    Google Scholar 

  91. Veronesi U, Adamus J, Aubert C, et al. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med 1982; 307: 913–6.

    Article  PubMed  CAS  Google Scholar 

  92. Tranum B, Frank J, Quagliana J, et al. Adjuvant chemo-therapy for stage I melanoma: a SWOG study. Proc Amer Soc Clin Oncol 1982; 1: 192.

    Google Scholar 

  93. Balch CM, Murray DR, Presant CA, et al. A randomized evaluation of adjunctive chemoimmunotherapy vs immuno-therapy in patients with resected metastatic melanoma. Int J Rad Oncol Biol Physics 1981; 7 (suppl 1): 38.

    Article  Google Scholar 

  94. Hill II GJ, Moss SE, Golomb FM, DTIC and combination therapy for melanoma. III. DTIC (MSC-45388) surgical adjuvant study COG protocol 7040. Cancer 1981; 2556–62.

    Google Scholar 

  95. Rege VB, Leone LA, Soderberg CH, et al. Hyperthermic adjuvant perfusion chemotherapy for stage I malignant melanoma of the extremity with literature review. Cancer 1983; 52: 2033–9.

    Article  PubMed  CAS  Google Scholar 

  96. Stehlin Jr J.S, Giovanella B.C, Gutierrez A.E, et al. 15 years’ experience with hyperthermic perfusion for treatment of soft tissue sarcoma and melanoma of the extremities. Front Rad Ther Oncol 1984; 18: 177–82.

    Google Scholar 

  97. Krementz ET. Chemotherapy by isolated regional perfusion for melanoma of the limbs. In: Vascular Perfusion in Cancer Therapy. Rec Res Cancer Res, vol 86, (Eds) Schwemmle K, Aigner K, Berlin: Springer-Verlag, pp. 193–203, 1983.

    Google Scholar 

  98. Schraffordt Koops H, Oldhoff J. Isolated perfusion of the extremities: Hyperthermic regional perfusion in high-risk stage I malignant melanomas of the extremities. In: Vascular Perfusion in Cancer Therapy, Rec Res Cancer Res, vol 86, Schwemmle K, Aigner K, Berlin: Springer-Verlag, pp. 223–8, 1983.

    Google Scholar 

  99. Tonak J, Hohenberger W, Weidner, et al. Hyperthermic perfusion in malignant melanoma. In: Vascular Perfusion in Cancer Therapy. Rec Res Cancer Res, vol 86, (Eds) Schwemmle K, Aigner K, Berlin: Springer-Verlag, pp. 229–38, 1983.

    Google Scholar 

Download references

Authors
  1. Ph. Rümke
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Pathology, University Medical Center, Leiden, The Netherlands

    Dirk J. Ruiter MD

  2. Department of Pathology, Faculty of Medicine, University of Leiden, Wassenaarseweg 62, 2333 AL, Leiden, The Netherlands

    Dirk J. Ruiter MD

  3. Department of Surgical Oncology, University Medical Center, Leiden, The Netherlands

    Kees Welvaart MD

  4. Department of Surgery, University Hospital, Rijnsburgerweg 10, 2333 AA, Leiden, The Netherlands

    Kees Welvaart MD

  5. Department of Microbiology and Immunology, New York Medical College, Valhalla, New York, USA

    Soldano Ferrone MD

Rights and permissions

Reprints and permissions

Copyright information

© 1984 Martinus Nijhoff Publishers, Dordrecht

About this chapter

Cite this chapter

Rümke, P. (1984). The Use of Chemotherapy in the Management of Patients with Malignant Melanoma. In: Ruiter, D.J., Welvaart, K., Ferrone, S. (eds) Cutaneous Melanoma and Precursor Lesions. Developments in Oncology, vol 25. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-6057-2_14

Download citation

  • DOI: https://doi.org/10.1007/978-94-009-6057-2_14

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-009-6059-6

  • Online ISBN: 978-94-009-6057-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation